TO TORNTPHARM
Torrent Pharmaceuticals Q3 2025
TOTORNTPHARM

Torrent Pharmaceuticals Q3 FY25 results (Oct–Dec 2024) and concall

Healthcare · Concall AI · Call held 24 Jan 2025

Management summary

  • Torrent Pharma delivered a resilient Q3 FY25, characterized by strong outperformance in the India branded chronic segment and a recovery in the insulin CMO business.
  • While headline revenue growth was muted at 3% due to temporary insulin facility downtime and Brazilian currency depreciation, underlying EBITDA growth remained healthy at 12% on a normalized basis.
  • Management remains focused on margin expansion and strategic entries into the GLP-1 market by 2026.

Source: Inve concall analysis and management guidance record.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25
Revenue2,377
EBITDA887
Net profit485
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Margin

  • Operating EBITDA Margin Margin · FY25 · High confidence 32.5%

    Previously 31.4% → 32.5%

  • Annual Margin Improvement Margin · Annually · Medium confidence 50-100 bps

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Insulin CMO Recovery and Margin Impact Direct
So, over and above run rate of 75-80, there should be a significant spillover which you will see in Quarter 4.

Confirms that the Q3 revenue drag was temporary and will reverse with high-margin spillover in Q4.

Asked by Damayanti Kerai, HSBC

Brazil Currency Depreciation vs. Price Increases Direct
I would be expecting a higher level of price increase allowed to us by the government, more in the close to the double-digit number as compared to middle or single digit in the last three, four years.

Management expects government-mandated price hikes in April to offset the significant BRL depreciation impact.

Asked by Damayanti Kerai, HSBC

Unlock risks & concerns, Q4 FY25 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 3 risks, concerns & management red flags
  • Watchlist triggers for Q4 FY25
  • +3 more guidance targets & verbatim management quotes
  • +1 more analyst Q&A exchange & evasion checks
  • Full section-by-section call narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image